Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus

NCT05056051 · View on ClinicalTrials.gov ↗

Study Summary

Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.

Interventions

  • DEVICE WATS-3D tissue sampling prior to forceps biopsies
  • DEVICE WATS-3D tissue sampling following forceps biopsies

Study Locations (4)

California

  • University of California, LA — Los Angeles

Colorado

  • University of Colorado — Aurora

Illinois

  • Northwestern Memorial Hospital — Chicago

Missouri

  • Washington University in St. Louis, Barnes Jewish Hospital — St Louis

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-10-01
Est. Completion 2025-06-30
Phase NA

Sponsor

Northwestern University

1,033 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05056051

The ClinicalTrials.gov registry entry for NCT05056051 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,033 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions — of which WATS-3D tissue sampling prior to forceps biopsies is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05056051 reports 4 study locations spanning 4 distinct geographic areas — top geographies include California, Colorado, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05056051 about?

NCT05056051 is a clinical study titled "Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus". Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barre...

What is the current status of trial NCT05056051?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2020-10-01. Estimated completion is 2025-06-30.

What conditions does trial NCT05056051 study?

This clinical trial studies the following conditions: Esophageal Cancer, Barrett Esophagus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05056051?

The interventions under investigation include: WATS-3D tissue sampling prior to forceps biopsies (DEVICE), WATS-3D tissue sampling following forceps biopsies (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05056051?

This trial is sponsored by Northwestern University, which has 1,033 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05056051 being conducted?

This trial has 4 study locations across California, Colorado, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial